Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 120,700 | 110,565 | 116,633 | 5,882 | 2,732 |
| Cost of Goods | 6,563 | 3,653 | 2,639 | 2,084 | 598 |
| Gross Profit | 114,137 | 106,912 | 113,994 | 3,798 | 2,134 |
| Operating Expenses | 259,899 | 241,843 | 219,005 | 229,909 | 194,482 |
| Operating Income | -145,199 | -134,278 | -104,372 | -226,027 | -191,750 |
| Interest Expense | 48,149 | 37,637 | 42,141 | 29,821 | 23,061 |
| Other Income | 6,866 | -9,743 | -23,095 | -10,388 | 50,557 |
| Pre-tax Income | -186,482 | -181,658 | -169,608 | -266,236 | -164,254 |
| Income Tax | -1,545 | 2,100 | N/A | N/A | N/A |
| Net Income Continuous | -184,937 | -183,758 | -169,608 | -267,389 | -164,254 |
| Minority Interests | -2,194 | -1,855 | -2,186 | -2,339 | -2,214 |
| Net Income | $-182,743 | $-181,903 | $-167,422 | $-265,050 | $-162,040 |
| EPS Basic Total Ops | -0.95 | -0.95 | -0.88 | -1.43 | -0.86 |
| EPS Basic Continuous Ops | -0.96 | -0.96 | -0.89 | -1.44 | -0.87 |
| EPS Diluted Total Ops | -0.95 | -0.95 | -0.88 | -1.43 | -0.86 |
| EPS Diluted Continuous Ops | -0.96 | -0.96 | -0.89 | -1.44 | -0.87 |
| EPS Diluted Before Non-Recurring Items | -0.95 | -0.95 | -0.88 | -1.31 | -0.86 |
| EBITDA(a) | $-143,801 | $-132,961 | $-103,088 | $-224,660 | $-190,212 |